A Phase I Study of Safety, Pharmacokinetics and Efficacy of HMPL-523 With Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs HMPL 523 (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hutchison MediPharma
- 18 Nov 2019 Status changed from recruiting to discontinued.
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 30 Sep 2018.